Market Overview
Neovascular age-related macular degeneration (AMD), also known as wet AMD, is a leading cause of vision loss, primarily affecting older adults. It is characterized by the growth of abnormal blood vessels beneath the retina, which leads to fluid leakage and scarring. This condition often results in a rapid deterioration of central vision, which can severely impact a patient's quality of life. Early diagnosis and treatment are crucial to managing AMD and preventing further vision loss.
The global neovascular age-related macular degeneration treatment market was valued at USD 11 billion in 2024 in the 7 major markets (7MM), which includes the United States, the European Union (EU-4 and the UK), and Japan. The market is expected to grow at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2025-2034, reaching an estimated value of USD 21.1 billion by 2034. This growth is driven by advancements in treatment technologies, increased awareness about the disease, and the rising prevalence of AMD among the aging population.
Market Size and Share
The neovascular AMD treatment market is projected to experience robust growth over the next decade. As of 2024, the market is valued at USD 11 billion across the 7MM, with a forecasted growth rate of 7.5% CAGR, bringing the market value to USD 21.1 billion by 2034. The growth of this market is primarily driven by continuous innovations in drug therapies, such as anti-VEGF agents, which play a key role in managing neovascular AMD. Moreover, as the global population ages, the number of individuals affected by AMD continues to increase, thereby boosting demand for treatment solutions.
In terms of market share, North America holds the largest share of the market, driven by a well-established healthcare infrastructure, high awareness of the disease, and an increasing number of individuals diagnosed with AMD. Europe and Japan also represent significant market opportunities due to the aging population and government initiatives to improve healthcare outcomes for older individuals.
Market Trends
Advancements in Anti-VEGF Therapy
Anti-VEGF (vascular endothelial growth factor) therapy remains the cornerstone of treatment for neovascular AMD. Drugs like Ranibizumab, Aflibercept, and Bevacizumab are widely used to inhibit the growth of abnormal blood vessels in the retina, which is a hallmark of wet AMD. Newer anti-VEGF therapies, such as Brolucizumab and Faricimab, are being developed to enhance treatment efficacy, reduce injection frequency, and minimize side effects. These advancements are expected to drive significant growth in the market during the forecast period.
Increased Adoption of Combination Therapies
Combination therapies are gaining popularity as they offer enhanced therapeutic benefits for neovascular AMD. By combining different drug types or adding corticosteroids or laser therapies to anti-VEGF injections, clinicians aim to improve treatment outcomes and minimize the need for frequent injections. The development and approval of combination therapies are expected to increase the number of treatment options available for patients, contributing to market growth.
Rising Prevalence of AMD
The prevalence of AMD is increasing globally, especially as the population ages. The growing geriatric population, particularly individuals aged 60 and older, is a key factor contributing to the rise in AMD cases. In developed regions such as North America, Europe, and Japan, the elderly population is expanding, resulting in more individuals being diagnosed with neovascular AMD. As a result, there is an increasing demand for effective treatment options, further driving the market’s growth.
Expansion of Access to Treatment in Emerging Markets
While the neovascular AMD treatment market has been traditionally driven by developed markets like North America, Europe, and Japan, there is an increasing trend toward expanding access to treatment in emerging markets. Rising healthcare awareness, improvements in healthcare infrastructure, and the growing affordability of treatments are making AMD therapies more accessible in countries such as China and India. This expansion into emerging markets is expected to provide significant growth opportunities for the neovascular AMD treatment market in the coming years.
Market Analysis
Scope of the Report
This report provides a comprehensive analysis of the neovascular AMD treatment market, examining historical and forecast trends, industry drivers, challenges, and market segmentation. The report covers key segments, including drug type, disease type, age group, disease stage, gender, and distribution channel, offering insights into the factors contributing to market growth. Additionally, it discusses regional trends and the competitive landscape of the market, identifying key players and their strategies in the neovascular AMD treatment space.
Historical and Forecast Trends
Historically, the market for neovascular AMD treatment has been driven by the development of anti-VEGF therapies, which have revolutionized the management of the disease. The market is expected to continue to grow at a CAGR of 7.5% due to ongoing advancements in drug development, including long-acting formulations and combination therapies. The forecast trends indicate that the growing global prevalence of AMD, coupled with increasing healthcare access in emerging markets, will drive further growth in the market.
Industry Drivers and Constraints
The primary drivers of market growth include the increasing prevalence of AMD, advancements in treatment technologies, and the availability of multiple therapeutic options for patients. Additionally, the expansion of access to healthcare in developing regions is contributing to market growth. However, the high cost of treatment, particularly in emerging markets, remains a constraint. Additionally, the complexity of managing neovascular AMD and the potential side effects associated with therapies present challenges in the widespread adoption of available treatments.
Market Analysis by Segment
The market for neovascular AMD treatment is segmented based on various factors:
Drug Type: The market includes key drugs like Ranibizumab, Aflibercept, Bevacizumab, and newer therapies like Brolucizumab and Faricimab.
Disease Type: The market is categorized into dry AMD and wet AMD (neovascular AMD), with the latter driving the majority of the treatment demand.
Age Group: The majority of patients with neovascular AMD are aged 60 and above, with a significant number of cases in individuals over 80 years old.
Disease Stage: Treatment demand varies based on the disease stage, with patients in late-stage AMD requiring more intensive interventions.
Regional Insights
United States
The United States is the largest market for neovascular AMD treatments, accounting for a significant portion of the global market share. The U.S. has a well-established healthcare infrastructure, high treatment adoption rates, and advanced healthcare facilities. The aging population and high prevalence of AMD further contribute to the demand for treatment. Moreover, the availability of innovative treatment options, including newer anti-VEGF agents, and government programs to address age-related diseases will continue to support the market in the U.S.
Japan
Japan is another significant market for neovascular AMD treatment. The country has a rapidly aging population, making it a key market for AMD treatment solutions. The Japanese government has been proactive in implementing policies to improve healthcare access for the elderly, which has further boosted the demand for AMD therapies. Moreover, Japan’s strong focus on technological advancements in the healthcare sector supports the adoption of new treatment options, such as Faricimab and Brolucizumab.
Market Growth
The neovascular AMD treatment market is poised for substantial growth over the next decade. Key drivers include the increasing prevalence of AMD due to the aging population, advancements in treatment options, and the expansion of healthcare access in emerging markets. Additionally, the growing awareness of AMD and the importance of early detection will fuel demand for effective treatments. Opportunities for growth exist in developing markets, where healthcare infrastructure improvements and rising awareness about AMD are driving increased treatment adoption.
Get a Free Sample Report with a Table of Contents
Recent Developments & Challenges
New Drug Approvals
Several new anti-VEGF agents, such as Faricimab and Brolucizumab, have recently received approval, providing more treatment options for neovascular AMD patients. These drugs offer improved efficacy and reduced injection frequency compared to older treatments, making them an attractive choice for both healthcare providers and patients.
Regulatory Hurdles
Despite the promising developments in the AMD treatment space, regulatory hurdles and approval delays for new drugs can slow down market growth. Drug manufacturers need to navigate complex regulatory processes to bring new therapies to market, which can take several years.
Cost-Effectiveness of Treatment
The high cost of AMD treatments, especially in developed regions, remains a significant challenge. Patients may face financial barriers to accessing the most effective treatments, particularly if insurance coverage is limited. As a result, the market may see a growing demand for cost-effective alternatives and generic drug options.
Telemedicine and Remote Monitoring
The rise of telemedicine and remote monitoring solutions has enhanced the management of AMD, especially in underserved regions. Patients can now have virtual consultations with ophthalmologists and monitor their condition using telehealth platforms, which can improve treatment adherence and outcomes.
Key Players
F. Hoffmann-La Roche Ltd
Roche is a leader in the global neovascular AMD treatment market, known for its innovative anti-VEGF therapies like Ranibizumab (Lucentis). The company’s strong focus on research and development has enabled the introduction of new therapies, such as Faricimab, aimed at improving patient outcomes and reducing treatment burden. Roche continues to expand its portfolio in AMD and other ophthalmic diseases, solidifying its market position.
Bausch & Lomb
Bausch & Lomb is a key player in the AMD treatment space, offering a range of treatment options, including Bevacizumab (Avastin) and Aflibercept (Eylea). The company is also exploring the potential of combination therapies to further enhance the efficacy of its treatments. Bausch & Lomb’s strong distribution network and ongoing research efforts are expected to drive its continued success in the neovascular AMD market.
Novartis AG
Novartis is another prominent player in the neovascular AMD treatment market, known for its Aflibercept (Eylea) product. Novartis is actively involved in the development of next-generation therapies for AMD, with an emphasis on reducing treatment frequency and improving patient outcomes. The company’s strong research pipeline is poised to shape the future of neovascular AMD treatments.
Pfizer, Inc.
Pfizer, a leading global biopharmaceutical company, has made significant strides in the ophthalmic disease treatment market. Through its collaboration with other pharmaceutical companies, Pfizer is involved in the development of innovative treatments for neovascular AMD. The company’s strong presence in the healthcare sector and extensive distribution network will continue to drive its success in this market.
Other key players include AbbVie Inc., Santen Pharmaceutical Co., Ltd., Ophthotech Corporation, Alimera Sciences, GSK plc. and Bayer AG.
FAQs
What is the primary treatment for neovascular AMD?
The primary treatment for neovascular AMD involves anti-VEGF therapies like Ranibizumab (Lucentis), Aflibercept (Eylea), and Bevacizumab (Avastin), which inhibit abnormal blood vessel growth in the retina.
How does neovascular AMD differ from dry AMD?
Neovascular AMD, or wet AMD, involves the growth of abnormal blood vessels beneath the retina, leading to vision loss. Dry AMD, the more common form, results from the gradual breakdown of retinal cells but typically causes slower vision deterioration.
What are the challenges in treating neovascular AMD?
Challenges include the high cost of treatment, the need for frequent injections, and the potential for side effects associated with some therapies. Additionally, early detection and timely intervention are crucial to prevent permanent vision loss.
Which drugs are currently approved for treating neovascular AMD?
Approved drugs for neovascular AMD treatment include Ranibizumab (Lucentis), Aflibercept (Eylea), Bevacizumab (Avastin), Brolucizumab (Beovu), and Faricimab (Vabysmo).
Read Our Blogs
Global Vessel Sealing Device Market: Top 9 Leading Providers & Innovations
